SCHEMBL5426197

SCHEMBL5426197

O=S(=O)(c1ccc(F)cc1Br)N1CCC(N2COCc3ccccc32)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 1/20 0.46
▸ HTR6 P50406 4/20 0.41
▸ TSHR P16473 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.38
▸ HTR2A P28223 2/20 0.37
▸ HTR2C P28335 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ CHRM1 P11229 2/20 0.36
▸ DRD2 P14416 1/20 0.36
▸ HTT P42858 2/20 0.35
▸ CCR1 P32246 2/20 0.35
▸ NR3C2 P08235 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ PKM P14618 1/20 0.34
▸ PKLR P30613 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5429985 0.86 HTR6 (0.41) EPHX2HTR6LMNARXFP1HTR2A
SCHEMBL5785930 0.86 PKM (0.41) HTR6TSHRLMNARXFP1HTR2A
SCHEMBL3156022 0.82 HTR6 (0.63) EPHX2HTR6
SCHEMBL5783205 0.82 HTR6 (0.42) HTR6TSHRLMNARXFP1HTR2A
SCHEMBL5426162 0.81 HTR6 (0.45) EPHX2HTR6TSHRLMNAHPGD
SCHEMBL5419801 0.80 CCR1 (0.42) EPHX2HTR6TSHRLMNAHPGD
SCHEMBL5426366 0.80 HTR6 (0.47) HTR6LMNARXFP1HTR2AHTR2C
SCHEMBL5428107 0.79 HTR6 (0.47) HTR6TSHRCCR1CYP3A4CYP2C9
SCHEMBL5421769 0.78 KMT2A (0.54) HTR6LMNAMEN1KMT2APKM
SCHEMBL5423035 0.78 ABL1 (0.45) TSHRLMNAMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032482-A1 Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2007-02-08 — — US claimed
US-20070032482-A1 Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2007-02-08 — — US disclosed
EP-1648886-A1 BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2006-04-26 — — EP disclosed
WO-2005014589-A1 BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE S.A. (DE) 2005-02-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032482-A1 Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments HTR6, HTR5A, P2RX6 EPHX2 2092/4885HTR6 1/4885TSHR 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback